Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists
about
Repeated use of albuterol inhaler as a potential cause of Takotsubo cardiomyopathy.Differential regulation of β2 -adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle.β₂ AR agonists in treatment of chronic heart failure: long path to translation.Adverse effects of beta-agonists: are they clinically relevant?The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study.Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery.Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services.A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction.Prospective cohort study of adverse events monitored by hospital pharmacists. Hospital Adverse Event Monitoring Study (HAEMS) Group.The effects of treatment in patients with childhood asthma on the elastic properties of the aortaHeart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challengesRisk of myocardial ischaemia and beta-adrenoceptor agonists.Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD).Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.
P2860
Q33645243-056DAE1E-7108-47F7-900C-CC8FF57B2FCDQ34449709-0353FCDD-E323-4DFE-B795-33CCBA5D1730Q34634348-DBB4F699-DAE8-4CC9-ADD0-62E9A68D7E81Q35627643-F2B11B6B-7B6B-4D8E-9831-88CE2D0ACFD7Q35799635-A58E68BC-4F04-471E-90EA-A3D684169BC5Q36342091-C38B582B-A015-4879-87F0-1EF97E910B6FQ37397232-66DB15C1-4442-42CB-9457-FD947E468343Q38119867-AA887A0B-E052-44A1-9548-4893A86C7A0CQ39742481-C9D31344-1600-40A8-865A-C691AE180617Q40692156-90270B3E-D0BC-4407-B4ED-8D76EFF68A65Q41426638-B3C9E989-F797-41C0-8EA6-347694E933F5Q42389709-58FA4EBA-FBA6-441B-B8A4-2C8A638B0F06Q44260780-52D1466E-78E8-456D-8D7D-E9C1BD8E0DF3Q44794033-4DE46A80-98E1-4C10-877A-4DA0E1FBC531Q47792766-4F705BCF-D808-4B1B-97FD-F3559609BFBB
P2860
Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@ast
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@en
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@nl
type
label
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@ast
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@en
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@nl
prefLabel
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@ast
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@en
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@nl
P2093
P2860
P356
P1433
P1476
Risk of non-fatal cardiac fail ...... th long acting beta 2 agonists
@en
P2093
R M Martin
S N Freemantle
P2860
P304
P356
10.1136/THX.53.7.558
P407
P577
1998-07-01T00:00:00Z